Matthias Hebrok, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Matthias Hebrok, PhD

Professor in Residence and Director, Diabetes Center, UCSF
Hurlbut-Johnson Distinguished Professor in Diabetes Research

mhebrok@diabetes.ucsf.edu

Phone: (415) 514-0820 (voice)
Box 0540, UCSF
San Francisco, CA 94143-0540

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics

Research Summary

My work focuses on understanding the mechanisms underlying pancreas development and disease, including diabetes and pancreatic cancer. My research on the role of embryonic signaling pathways in these processes has provided a glimpse into how tight regulation of these signaling events is imperative for proper organogenesis, maintenance of organ function, and prevention of pancreatic cancer. My lab has made important insights into how differentiated cells in the exocrine pancreas, namely duct and acinar cells, undergo a process of dedifferentiation during the early stages of neoplasia that can lead to pancreatic ductal adenocarcinoma (PDA), a particularly lethal cancer in humans.

Education

Biological-Technical Assistant (BTA) School, Bückeburg, Germany, Diploma, 1983-1985, Biology
Albert-Ludwigs University, Freiburg, Germany, Diploma/ Master Ph.D., 1986-1992, Cell & Molecular Biology
Max-Planck-Institute for Immunobiology, Freiburg, Germany, 1992-1995, Developmental Biology
Harvard University, Department of Molecular & Cell Biology and Howard Hughes Medical Institute, Cambridge, MA Postdoctoral Training, 1996-1999, Developmental Biology


Professional Experience

  • 1991-1992
    Diploma thesis, Institute for Immunobiology, Dept. of Tumorbiology, Dr. W. Bessler, advisor
  • 1992-1995
    Graduate student, Max-Planck-Institute for Immunobiology, Freiburg, Dept. of Developmental Biology, Dr. Ernst-Martin Füchtbauer, advisor; Dr. Davor Solter, Head of Department
  • 1995
    Post-doctoral Research Fellow, Max-Planck-Institute for Immunobiology in Freiburg, Dept. of Developmental Biology
  • 1996-1999
    Postdoctoral Research Fellow, Howard Hughes Medical Institute and Dept. of Molecular and Cellular Biology, Harvard University, Dr. Douglas A. Melton, advisor
  • 1999-2005
    Assistant Professor in Residence, Diabetes Center, University of California, San Francisco
  • 2005-2009
    Associate Professor, Diabetes Center, University of California, San Francisco
  • 2008
    Interim Director, Diabetes Center, University of California, San Francisco
  • 2009-2010
    Associate Director of Research, Diabetes Center, University of California, San Francisco
  • 2009-present
    Professor of Medicine, Diabetes Center, University of California, San Francisco
  • 2010
    Interim Director, Diabetes Center, University of California, San Francisco
  • 2010-present
    Director, Diabetes Center, University of California, San Francisco

Honors & Awards

  • 1994
    Graduate Student Research Award of the Hoechst AG, Frankfurt
  • 1995
    Post-doctoral Fellowship from the Max-Planck Society
  • 1996
    Post-doctoral Fellowship from the German Research Society (DFG)
  • 1997-1999
    Howard Hughes Medical Institute Postdoctoral Fellowship
  • 1999
    Sandler Program in Basic Sciences Junior Faculty Start-up Award
  • 2000
    Sandler Award in Basic Sciences
  • 2000
    Career Development Award, Juvenile Diabetes Foundation
  • 2004
    Guest-Professor, University of Ulm, Germany
  • 2006
    Scholar Award, Juvenile Diabetes Research Foundation
  • 2013-present
    Chair, CADO/NIH study section

Selected Publications

  1. Human pancreatic beta-like cells converted from fibroblasts. Nat Commun. 2016; 7:10080.
    View on PubMed
  2. Regulation of Cellular Identity in Cancer. Dev Cell. 2015 Dec 21; 35(6):674-84.
    View on PubMed
  3. ß-Cell Insulin Secretion Requires the Ubiquitin Ligase COP1. Cell. 2015 Dec 3; 163(6):1457-67.
    View on PubMed
  4. Dynamic Proteomic Analysis of Pancreatic Mesenchyme Reveals Novel Factors That Enhance Human Embryonic Stem Cell to Pancreatic Cell Differentiation. Stem Cells Int. 2016; 2016:6183562.
    View on PubMed
  5. Human stem cells from single blastomeres reveal pathways of embryonic or trophoblast fate specification. Development. 2015 Dec 1; 142(23):4010-25.
    View on PubMed
  6. DNA methylation directs functional maturation of pancreatic ß cells. J Clin Invest. 2015 Jul 1; 125(7):2851-60.
    View on PubMed
  7. Controlled induction of human pancreatic progenitors produces functional beta-like cells in vitro. EMBO J. 2015 Jul 2; 34(13):1759-72.
    View on PubMed
  8. Islet formation in mice and men: lessons for the generation of functional insulin-producing ß-cells from human pluripotent stem cells. Curr Opin Genet Dev. 2015 Jun; 32:171-80.
    View on PubMed
  9. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Genes Dev. 2015 Mar 15; 29(6):658-71.
    View on PubMed
  10. CDK1 Inhibition Targets the p53-NOXA-MCL1 Axis, Selectively Kills Embryonic Stem Cells, and Prevents Teratoma Formation. Stem Cell Reports. 2015 Mar 10; 4(3):374-89.
    View on PubMed
  11. NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas. Gastroenterology. 2015 May; 148(5):1024-1034.e9.
    View on PubMed
  12. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. EMBO J. 2015 Feb 12; 34(4):517-30.
    View on PubMed
  13. Plasticity and dedifferentiation within the pancreas: development, homeostasis, and disease. Cell Stem Cell. 2015 Jan 8; 16(1):18-31.
    View on PubMed
  14. Taming the young and restless-epigenetic gene regulation in pancreas and beta-cell precursors. EMBO J. 2014 Oct 1; 33(19):2135-6.
    View on PubMed
  15. Aberrant innate immune activation following tissue injury impairs pancreatic regeneration. PLoS One. 2014; 9(7):e102125.
    View on PubMed
  16. Dicer regulates differentiation and viability during mouse pancreatic cancer initiation. PLoS One. 2014; 9(5):e95486.
    View on PubMed
  17. Diabetes. Solving human ß-cell development--what does the mouse say? Nat Rev Endocrinol. 2014 May; 10(5):253-5.
    View on PubMed
  18. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol. 2014 Mar; 16(3):255-67.
    View on PubMed
  19. Small molecules facilitate the reprogramming of mouse fibroblasts into pancreatic lineages. Cell Stem Cell. 2014 Feb 6; 14(2):228-36.
    View on PubMed
  20. VHL-mediated disruption of Sox9 activity compromises ß-cell identity and results in diabetes mellitus. Genes Dev. 2013 Dec 1; 27(23):2563-75.
    View on PubMed

Go to UCSF Profiles, powered by CTSI